Skip to main content
Log in

Morbus Coats

Coats disease

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Unter Morbus Coats versteht man eine Erkrankung, die durch idiopathische kongenitale retinale Teleangiektasien und eine dadurch bedingte exsudative Retinopathie charakterisiert ist. Sie betrifft hauptsächlich junge, männliche Patienten und ist fast immer unilateral. Je nach Ausprägungsgrad der exsudativen Komponente variiert die Visusprognose von vollem Visus bis zur vollständigen Erblindung. Differenzialdiagnostisch muss der Morbus Coats gerade bei Kleinkindern von einem Retinoblastom unterschieden werden, aber auch andere Ursachen für eine exsudative Retinopathie kommen in Frage. Die Behandlung zielt auf eine Verödung der Teleangiektasien, um eine Verringerung der Exsudation und eine Wiederanlage der Netzhaut zu erreichen. Als Therapieoptionen stehen Laser- oder Kryokoagulation, Ablassung der subretinalen Flüssigkeit, Buckelchirurgie und Pars-plana-Vitrektomie zur Verfügung. In fortgeschrittenen Fällen mit therapieresistentem Sekundärglaukom kann eine Enukleation des betroffenen Auges nötig werden. Neuerdings kann auch die intravitreale Gabe von VEGF-Inhibitoren erwogen werden.

Abstract

Coats disease is characterized by idiopathic congenital retinal telangiectasis and exudative retinopathy. Mostly young males are affected. The disease is usually unilateral. Visual prognosis varies from full visual acuity to blindness according to the extent of retinal exudation. Retinoblastoma is a major differential diagnosis particularly in small children but other causes of exudative retinopathy must also be considered. Treatment aims include obliteration of the telangiectasis in order to resolve retinal exudation and achieve reattachment of the retina. Therapeutic options comprise laser coagulation or cryotherapy, drainage of subretinal fluid, buckling surgery and pars plana vitrectomy. In more advanced cases with therapy-resistant secondary glaucoma enucleation may be required. More recently, intravitreal administration of VEGF inhibitors has become an option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7

Literatur

  1. Berger W, Van De Pol D, Bachner D et al (1996) An animal model for Norrie disease (ND): gene targeting of the mouse ND gene. Hum Mol Genet 5:51–59

    Article  CAS  PubMed  Google Scholar 

  2. Bergstrom CS, Hubbard GB 3rd (2008) Combination intravitreal triamcinolone injection and cryotherapy for exudative retinal detachments in severe Coats disease. Retina 28:S33–S37

    Article  PubMed  Google Scholar 

  3. Black GC, Perveen R, Bonshek R et al (1999) Coats‘ disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Genet 8:2031–2035

    Article  CAS  PubMed  Google Scholar 

  4. Coats G (1908) Forms of retinal diseases with massive exudation. Royal Lond Ophthalmol Hosp Rep 17:440–525

    Google Scholar 

  5. Coats G (1912) Ueber retinitis exudativa (retinitis hemorrhagica externa). Albrecht Von Graefes Arch Klin Exp Ophthalmol 81:275–327

    Article  Google Scholar 

  6. Deutsch TA, Rabb MF, Jampol LM (1982) Spontaneous regression of retinal lesions in Coats‘ disease. Can J Ophthalmol 17:169–172

    CAS  PubMed  Google Scholar 

  7. Gass JD (1971) Cavernous hemangioma of the retina. A neuro-oculo-cutaneous syndrome. Am J Ophthalmol 71:799–814

    CAS  PubMed  Google Scholar 

  8. Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536–1546

    CAS  PubMed  Google Scholar 

  9. Goel SD, Augsburger JJ (1991) Hemorrhagic retinal macrocysts in advanced Coats disease. Retina 11:437–440

    CAS  PubMed  Google Scholar 

  10. Junker B, Schmidt D, Agostini HT (2007) Retinal angiomatosis. Ocular manifestation of von Hippel-Lindau disease. Ophthalmologe 104:107–113

    Article  CAS  PubMed  Google Scholar 

  11. Khan JA, Ide CH, Strickland MP (1988) Coats’-type retinitis pigmentosa. Surv Ophthalmol 32:317–332

    Article  CAS  PubMed  Google Scholar 

  12. Leber T (1912) Ueber eine durch Vorkommen multipler Miliaraneurysmen charakterisierte Form von Retinaldegeneration. Albrecht Von Graefes Arch Klin Exp Ophthalmol 81:1–14

    Article  Google Scholar 

  13. Lin CJ, Hwang JF, Chen YT, Chen SN (2009) The effect of intravitreal bevacizumab in the treatment of coats disease in children. Retina: Epub ahead of print

  14. Machemer R, Williams JM Sr (1988) Pathogenesis and therapy of traction detachment in various retinal vascular diseases. Am J Ophthalmol 105:170–181

    CAS  PubMed  Google Scholar 

  15. Meier P (2008) Retinal detachment in children: differential diagnosis and current therapy. Klin Monatsbl Augenheilkd 225:779–790

    Article  CAS  PubMed  Google Scholar 

  16. Reese AB (1956) Telangiectasis of the retina and Coats‘ disease. Am J Ophthalmol 42:1–8

    CAS  PubMed  Google Scholar 

  17. Robitaille JM, Monsein L, Traboulsi EI (1996) Coats‘ disease and central nervous system venous malformation. Ophthalmic Genet 17:215–218

    Article  CAS  PubMed  Google Scholar 

  18. Schafer NF, Luhmann UF, Feil S, Berger W (2009) Differential gene expression in Ndph-knockout mice in retinal development. Invest Ophthalmol Vis Sci 50:906–916

    Article  PubMed  Google Scholar 

  19. Orphanet Report Series (2009) Prevalence of rare diseases: Bibliographic data, Rare Diseases collection, Number 1: Listed in alphabetical order of diseases. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf

  20. Shields JA, Shields CL (2001) Differentiation of coats‘ disease and retinoblastoma. J Pediatr Ophthalmol Strabismus 38:262–266; quiz 302–263

    CAS  PubMed  Google Scholar 

  21. Shields JA, Shields CL (2002) Review: coats disease: the 2001 LuEsther T. Mertz lecture. Retina 22:80–91

    Article  PubMed  Google Scholar 

  22. Shields JA, Shields CL, Ehya H et al (1993) Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology 100:1677–1684

    CAS  PubMed  Google Scholar 

  23. Shields JA, Shields CL, Honavar SG, Demirci H (2001) Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol 131:561–571

    Article  CAS  PubMed  Google Scholar 

  24. Shields JA, Shields CL, Honavar SG et al (2001) Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalmol 131:572–583

    Article  CAS  PubMed  Google Scholar 

  25. Sun Y, Jain A, Moshfeghi DM (2007) Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol 245:1387–1388

    Article  CAS  PubMed  Google Scholar 

  26. Tarkkanen A, Laatikainen L (1983) Coat’s disease: clinical, angiographic, histopathological findings and clinical management. Br J Ophthalmol 67:766–776

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B. Junker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Junker, B., Hansen, L. Morbus Coats. Ophthalmologe 107, 379–390 (2010). https://doi.org/10.1007/s00347-010-2151-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-010-2151-6

Schlüsselwörter

Keywords

Navigation